Series B · Biotech
Vaderis Therapeutics: Series B
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Funding history
Series B · This round$152M
Loading rounds…
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia